Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Fineline Cube Jan 14, 2026
Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company Drug

Shanghai Pharmaceuticals’ Dual-Targeting CAR-T Therapy Advances with IND Re-Acceptance

Fineline Cube Sep 18, 2024

Shanghai Pharmaceuticals Group Co., Ltd. (SHA: 601607)’s biotech subsidiary has announced that its investigational ‘CD19...

Company

Walsun Biotech Achieves Top ESG Rating, Underscores Commitment to Sustainability

Fineline Cube Sep 17, 2024

Yunnan Walsun Biotech Co., Ltd. has seen its ESG rating upgraded to BBB by MSCI,...

Company Drug

Novartis’ Cemiplimab Approved in China for Moderate-to-Severe Atopic Dermatitis

Fineline Cube Sep 16, 2024

Novartis (SWX: NOVN, NYSE: NVS)’s Chinese arm has announced that it has received approval from...

Company Hospital

Innovent Biologics Launches Phase I Clinical Trial for IBR822 Cell Injection Solution in Solid Tumors

Fineline Cube Sep 16, 2024

Innovent Biologics (Hangzhou) Co., Ltd (HKG: 1801, OTCMKTS: IVBXF), a biopharmaceutical company based in China,...

Company Drug

Johnson & Johnson’s Tremfya Gains FDA Approval for Ulcerative Colitis Treatment

Fineline Cube Sep 14, 2024

Johnson & Johnson (NYSE: JNJ) announced today that the US Food and Drug Administration (FDA)...

Company Deals

Sanofi Secures Global Rights to Radioligand Therapy AlphaMexi in Deal with RadioMedix and Orano Med

Fineline Cube Sep 14, 2024

Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant...

Company Drug

Roche’s Tecentriq Hybreza Becomes First Subcutaneous Anti-PD-(L)1 Immunotherapy in the US

Fineline Cube Sep 14, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY) , a leading Swiss pharmaceutical company, has secured US Food...

Company Drug

Lilly’s Once-Monthly Atopic Dermatitis Treatment Ebglyss Gets Green Light from FDA

Fineline Cube Sep 14, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that it has received market approval from...

Company Drug

Roche’s Ocrevus Zunovo Receives FDA Nod as First Twice-Yearly MS Treatment

Fineline Cube Sep 14, 2024

Roche Group (SWX: ROG; OTCMKTS: RHHBY) , a Swiss pharmaceutical giant, has announced that the...

Company Drug

Ascentage Pharma’s Olverembatinib Shows Promise in SDH-Deficient GIST at ESMO Congress

Fineline Cube Sep 14, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced the presentation of...

Company Deals

Fosun Pharma to Acquire Full Stake in Fosun Kite Biotechnology for USD 27 Million

Fineline Cube Sep 14, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has disclosed plans to acquire...

Company Drug

Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Receives Priority Review from China’s NMPA

Fineline Cube Sep 14, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals Medical Device

Hangzhou-Based Ophthalmic Device Maker MDCO Secures RMB 200 Million in Series B Funding

Fineline Cube Sep 14, 2024

MDCO, an ophthalmic medical device company headquartered in Hangzhou, has reportedly secured nearly RMB 200...

Company Deals

Beijing Wantai Biological and Fujian Provincial CDC Collaborate on Vaccine Development and Public Health Initiatives

Fineline Cube Sep 14, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading biopharmaceutical company based in...

Company Deals

MGI Tech and Haihe Laboratory Deepen Collaboration with Introduction of CycloneSEQ-WT02

Fineline Cube Sep 14, 2024

MGI Tech Co., Ltd, a prominent gene sequencing company based in China, has disclosed a...

Company Deals

MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research

Fineline Cube Sep 14, 2024

MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has entered into...

Policy / Regulatory

China Boosts Public Health Subsidies and Targets Weight Management in 2024

Fineline Cube Sep 14, 2024

The National Health Commission, Ministry of Finance, National Administration of Traditional Chinese Medicine, and National...

Policy / Regulatory

China’s NHSA and MOF Issue Notices to Enhance Cross-Regional Medical Treatment Direct Settlement

Fineline Cube Sep 14, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MOF) have issued two...

Policy / Regulatory

CDE Launches CARE Plan to Streamline Rare Disease Drug Development

Fineline Cube Sep 14, 2024

The Center for Drug Evaluation has unveiled the ‘Pilot Work Plan for Patient-Centered Action for...

Company

Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment

Fineline Cube Sep 13, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced...

Posts pagination

1 … 240 241 242 … 609

Recent updates

  • Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
  • ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination
  • Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors
  • U‑Yin Pharma’s EHT102 Gene Therapy Scores IND Approval Under NMPA’s 30‑Day Review for DFNB9 Hearing Loss
  • Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Company Drug

U‑Yin Pharma’s EHT102 Gene Therapy Scores IND Approval Under NMPA’s 30‑Day Review for DFNB9 Hearing Loss

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.